Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients

Table 3

Association of polymorphisms in antioxidative genes with NT-proBNP levels.

SNP	Genotype	NT-proBNP median (25-75%)	P	NT-proBNP <125 ng/l, (%)	NT-proBNP ≥125 ng/l, (%)	OR (95% CI)		OR (95% CI)adj
PON1 rs854560	AA	126 (59-200)		21 (50.0)	21 (50.0)	Reference		Reference
	AT+TT	79 (51-125)	0.048	44 (74.6)	15 (25.4)	0.34 (0.15-0.79)	0.012	0.35 (0.15-0.83)	0.017
PON1 rs662	AA	79 (47.75-118.5)		43 (79.6)	11 (20.4)	Reference		Reference
	AG+GG	135 (60-193)	0.007	22 (46.8)	25 (53.2)	4.44 (1.85-10.66)	0.001	5.41 (2.12-13.78)	<0.001
GSTP1 rs1138272	CC	92 (58-156)		53 (63.9)	30 (36.1)	Reference		Reference
	CT+TT	78.5 (36-165.5)	0.407	12 (66.7)	6 (33.3)	0.88 (0.30-2.56)	0.821	0.71 (0.23-2.16)	0.545
GSTP1 rs1695	GG	122 (65.75-174.5)		24 (54.5)	20 (45.5)	Reference		Reference
	GA+AA	77 (48.5-144)	0.101	41 (71.9)	16 (28.1)	0.47 (0.21-1.07)	0.073	0.36 (0.15-0.88)	0.026
CAT rs1001179	GG	88 (52.5-148.25)		42 (65.6)	22 (34.4)	Reference		Reference
	GA+AA	96 (56-182)	0.680	23 (62.2)	14 (37.8)	1.16 (0.50-2.70)	0.762	0.99 (0.41-2.36)	0.973
HIF1A rs1154965	CC	91 (56-154.5)		56 (63.6)	32 (36.4)	Reference		Reference
	CT+TT	79 (54.5-180)	0.666	9 (69.2)	4 (30.8)	0.78 (0.22-2.73)	0.695	0.87 (0.24-3.13)	0.827

Adj: adjusted for age; CI: confidence interval; NT-proBNP: N-terminal pro B-type natriuretic peptide; OR: odds ratio.